NEW YORK (GenomeWeb News) – Cancer Genetics said after the close of the market on Wednesday that its fourth quarter revenues increased 73 percent year over year.
For the three months ended Dec. 31, 2013 the Rutherford, NJ-based cancer diagnostics firm reported revenues of $1.9 million, up from $1.1 million in the year-ago quarter.
Net loss for the recently completed quarter shrank to $2.5 million, or $.37 per share, compared to a net loss of $4.0 million, or $3.86 per share, in Q4 2012. The firm, which went public in April 2013, used about 8.3 million shares to calculate its loss on a per-share basis in Q4 2013, compared to 1.3 million shares in the year-ago quarter.
Cancer Genetics said that its R&D costs ticked up 44 percent year over year in the quarter to $806,082 from $560,275, while its SG&A expenses rose 71 percent to $2.4 million from $1.4 million.
For full-year 2013, the company posted revenues of $6.6 million, up 53 percent from $4.3 million in 2013. Cancer Genetics President and CEO Panna Sharma said in a statement that ongoing adoption of the firm's tests and its "comprehensive approach to disease-specific oncology testing" drove revenue growth in 2013.
He added that Cancer Genetics ramped up its commercial team and expanded its pipeline into areas of high unmet needs, such as renal and cervical cancers.
"We are also on track in advancing our own next-generation sequencing programs and those in our joint venture, Oncospire Genomics with Mayo Clinic," Sharma said.
The company had a net loss of $12.4 million, or $3.64 per share, in 2013, compared to a net loss of $6.7 million, or $10.55 per share, in 2012.
Cancer Genetics used 4.7 million shares to calculate is loss-per-share figure in 2013 and 1.3 million shares for the 2012 figure.
Its R&D expenses increased 5 percent year over year last year to $2.2 million from $2.1 million in 2012, and its SG&A costs were up 36 percent to $8.0 million from $5.9 million.
The company exited 2013 with $49.5 million in cash and cash equivalents.